
About Oxford BioTherapeutics:
Oxford BioTherapeutics is a clinical-stage biotechnology company focusing on the development of antibody therapeutics for the treatment of cancer. OBT’s OGAP-verify® platform is the world's largest, cancer specific, membrane protein library, directly measuring plasma membrane protein expression in patient tumours. OGAP is used to identify novel, highly tumour specific antigens for novel first-in-class ADC, T-cell Engager (TCE) and Chimeric Antigen Receptor (CAR-T) targets. Our lead asset, OBT076, is an Antibody Drug Conjugate (ADC) in Phase 1b clinical development. Our clinical and pre-clinical pipeline of novel biologics is balanced between internal programs, focused on ADCs and checkpoint regulators, and externally partnered programs with key innovators in oncology such as Roche, GSK and Zymeworks.
Purpose of the Role
The role will lead the mass spectrometry proteomics laboratory work at OBT’s Oxford research facility. The role will generate quantitative proteomics data from human tissues in support of OBT’s OGAP verify, oncology target discovery platform, with the aim of identifying novel oncology drug targets for development with antibody-based drug therapies (ADCs, TCEs, CAR-T, Radiopharmaceuticals)
Roles and Responsibilities:
Please note the roles and responsibilities for the position include but are not limited to the above.
Knowledge, Experience, and Skills:
Essential:
Desirable:
One of our top priorities is to maintain the health and wellbeing of our employees and their families. To achieve this goal, we offer comprehensive benefits.
Benefits Offered:
Equal Opportunities Statement
We are committed to equality of opportunity for all employee and applications from individuals are encouraged regardless of age, disability, sex, gender reassignment, sexual orientation, pregnancy and maternity, race, religion or belief and marriage and civil partnerships.
Why Join Us
We promote a culture of innovation, responsibility, and collective commitment to our goals. We believe that by bringing together our diverse skills and perspectives, we can develop novel, robust cures for one of today’s most challenging health conditions.
Our people often describe OBT’s culture as friendly, collaborative, and hard‑working. We recognise that our team is only as strong as the individuals within it, which is why, in addition to hiring the best people, we strive to provide a working environment based on cooperation, creativity, and mutual respect.
Oxford BioTherapeutics (OBT) is a clinical stage oncology company based in Oxford, UK; San Jose, CA and Morristown, NJ, USA, with a pipeline of first-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) based therapies designed to fulfil major unmet patient needs in cancer therapeutics.
Our lead asset, OBT076, is an Antibody Drug Conjugate (ADC) in Phase 1b clinical development. OBT076's dual mechanism of action allows it to act as a 'primer' to re-engage the patient's immune system while at the same time targeting cancer cells directly.
OBT’s proprietary OGAP® target discovery platform is based on one of the world’s largest proprietary cancer membrane proteomic databases, with data on over 5,000 cancer cell proteins providing unique, highly qualified oncology targets, of which three programs are in clinical development in the USA and Europe.
The company’s pipeline and development capabilities have been validated through multiple strategic partnerships, including with Boehringer Ingelheim, ImmunoGen and Kite Pharma as well as other world leaders in antibody development (such as Amgen, WuXi, Medarex (BMS), Alere (Abbott)).
Take the next step in your career journey